Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695892 | 0.81 | LMNA (0.51) | KDM4EALDH1A1LMNAGAAMAPT | |
| SCHEMBL13589509 | 0.80 | TDP1 (0.48) | TGM2ENPP2CA1CA2CA9 | |
| SCHEMBL22424592 | 0.77 | ENPP2 (0.48) | TGM2ENPP2CA1CA2CA9 | |
| SCHEMBL6697721 | 0.76 | ALDH1A1 (0.57) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6701324 | 0.73 | ALDH1A1 (0.53) | CA1CA2CA12ALDH1A1LMNA | |
| SCHEMBL14624918 | 0.73 | CA12 (0.54) | TGM2ENPP2CA1CA2CA9 | |
| SCHEMBL14624184 | 0.73 | CA12 (0.54) | TGM2ENPP2CA1CA2CA9 | |
| SCHEMBL31020737 | 0.73 | ALDH1A1 (0.55) | TGM2ENPP2CA1CA2CA9 | |
| SCHEMBL6701040 | 0.72 | CA12 (0.42) | CA12KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL486575 | 0.71 | CA12 (0.64) | TGM2ENPP2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | TGM2 1067/4885ENPP2 821/4885CA1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.